$358.24

-3.56%

KRYS

Krystal Biotech, Inc.

•Healthcare

Rare Disease Therapeutics

Gene Therapy

Commercial Stage Biotech

High Growth

Rare Disease Therapeutics

Gene Therapy

Commercial Stage Biotech

High Growth

Loading Chart...

FIT ANALYSIS

Required for personalization

FIT ANALYSIS

Checking Membership...

STOCK DNA

Valuation

3/10

Quality

9/10

Growth

7/10

Strength

6/10

Dividend

1/10

Similar Stocks

ABEO Abeona Therapeutics Inc.

RARE Ultragenyx Pharmaceutical Inc.

FBIO Fortress Biotech, Inc.

PTCT PTC Therapeutics, Inc.

PVLA Palvella Therapeutics, Inc.

Health Indicators

Price Trend

Upwards

Momentum

Neutral

Balance Sheet

Healthy

Earnings

Growth

Dividend Yield

0.00%

Market Cap

$10.60B

TALK TO YOUR STOCK

EQUITAI ASSISTANT

Krystal Biotech develops and commercializes genetic medicines for patients with rare diseases. Its flagship product is a topical, redosable gene therapy that treats debilitating skin conditions. I have synthesized my analysis of its core fundamentals, live market action, and peer metrics to provide a comprehensive thesis. What specific areas can I detail for you?

AI can make mistakes. Verify important information.

Talk to Your Stock•open live chat

Pro EquitAI Research

Retrieving premium status...